By Elizabeth Renter
January 14, 2013
This article originally appeared on Natural Society
In our society today, newborns are injected with loads of chemicals nearly as soon as they enter the world. In the name of “prevention”, we give them vaccines that we aren’t even sure are safe.
As a matter of fact, in many cases, we know them to be unsafe.
This is the case with the hepatitis B vaccine, approved for infants at birth but admittedly responsible for causing serious illness and even death.
The United States Court of Federal Claims sided with the estate of Tambra Harris, who died as a result of an auto-immune disease called systemic lupose erythematosus (SLE).
The court awarded $475,000 following her death after finding the hepatitis vaccine caused her injury in the form of SLE. But this near-admittance of a cause-effect relationship between the vaccine and the illness and subsequent death isn’t enough. No, we still give the shot to babies.
So, what is hepatitis B and why are we told that it is so important that newborn infants are vaccinated against it? Hepatitis B is not pleasant and can be deadly. But newborns (and the vast majority of people at any age) aren’t at risk of contracting the disease.
It’s spread by contact with bodily fluids, as in through unprotected sex or dirty needles.
The risks associated with the hepatitis B vaccine are far more pressing than the risk of contracting the disease, says Dr. Jane Orient of the Association of American Physicians and Surgeons (AAPS).
“For most children, the risk of a serious vaccine reaction may be 100 times greater than the risk of hepatitis B.”
Still, newborns are given the vaccine within moments of entering the world.
Considered by many to be crimes against infants, the hep-b vaccination, the vaccine has been linked to sudden infant death syndrome (SIDS), multiple sclerosis, and other autoimmune disorders.
Many experts have questioned the prolific use of the vaccine since it stepped on the scene a few decades ago. What’s more, many parents are starting to question the need for the vaccine.
“In increasing numbers, parents across the country are contacting the National Vaccine Information Center (NVIC) to report opposition to regulations being enacted by state health department officials that legally require children to be injected with three doses of hepatitis B vaccine before being allowed to attend daycare, kindergarten, elementary school, high school or college,” National Vaccine Information Center reads.
As a parent, it is still your decision whether or not to vaccinate your child. There is plenty of research out there to help guide you in this decision. Don’t let your doctor or the people around you be your only source of information.
Do your research and determine the best solution for your child’s long-term health.
Monday, January 14, 2013 by: David Gutierrez, staff writer
“We were struck by the gravity of these findings,” said Steven H. Woolf of Virginia Commonwealth University, a member of the panel that issued the report.
“Americans are dying and suffering at rates that we know are unnecessary because people in other high-income countries are living longer lives and enjoying better health. What concerns our panel is why, for decades, we have been slipping behind.”
LONDON | Mon Jan 14, 2013 6:22am EST
(Reuters) – GlaxoSmithKline said on Monday it had filed for U.S. approval of its new once-weekly diabetes drug albiglutide and would make a similar submission shortly in Europe as it vies for a share of a crowded market.
Albiglutide belongs to the same class of injectable GLP-1 medicines as Victoza, from Novo Nordisk, and Byetta and Bydureon, from Bristol-Myers Squibb and AstraZeneca’s Amylin unit.
The submission by GSK, Britain’s biggest drugmaker, was in line with its plan to seek regulatory approval for the new product in 2013. As a latecomer to the GLP-1 market, however, analysts believe albiglutide may struggle to generate major sales.
Consensus forecasts for albiglutide currently point to modest annual sales of around $367 million by 2017, according to Thomson Reuters Pharma.
Albiglutide is one of a number of new drugs GSK hopes will revive its product portfolio. It is also hoping for approval of the two lung drugs, Relvar and Anoro; an HIV medicine called dolutegravir; and two melanoma drugs dabrafenib and trametinib.
Further ahead, GSK expects to have pivotal clinical trial results on up to 14 medicines in the next two years, including two potentially ground-breaking experimental drugs for heart disease and cancer – darapladib and MAGE-A3.
(Reporting by Ben Hirschler)
Injecting vaccinations into the thigh may be safer for toddlers than the arm, says a new study from researchers at the Group health Research Institute in Seattle. For the study the researchers examined health records from 1.4 million young children between the ages of 12 months and 35 months.
They found that those kids who received diphtheria, tetanus and pertussis (DTaP) vaccines through their leg were half as likely to return to doctors for infections at the injection site.
“These local reactions are the most common side effect of vaccinations, but we have known relatively little about how to prevent them,” say study leader Dr. Lisa Jackson. “Our findings support current recommendations to give intramuscular vaccinations in the thigh for children younger than 3 years.”
Their data appeared online this week in Pediatrics.
by RTT Staff Writer
Pharmaceuticals are now responsible for more deaths (37,485 dead in 2009) in the United States than traffic fatalities. Nevertheless, the mainstream medical community calls alternative medicine “dangerous,” and the government is all too happy to share the profits in attempting to demonize natural foods like raw milk and their providers whilst reinforcing potentially dangerous—and often unnecessary—flu shots. Peer-reviewed research shows that the good old sunshine nutrient, vitamin D, is more effective as slashing risk of cancer, obesity, tooth decay, and the flu than popular pharmaceuticals.
Furthermore, the Food and Drug Administration wants walnuts—which are high in omega 3 fatty acids and suspected of helping against breast cancer—to be labeled as “drugs.” According to the Alliance for Natural Health, the FDA is even looking to ban vitamin B6 supplements as we know it so Big Pharma—in this case, the company BioStratum—can patent and sell natural vitamin B sources.
Neither the industry sector nor members of our government entangled in it are interested in saving the public or any public institution money (never mind lives). They care about padding their pockets, and poor government review and regulation processes as well as plain bad science are partly to blame for making their jobs easier.
Sunday, January 13, 2013 by: Ethan A. Huff, staff writer
(NaturalNews) Greedily clawing for new ways to generate as much profit as logistically possible, the pharmaceutical industry has taken a renewed interest in developing novel drugs for so-called “orphan” diseases, or extremely rare health conditions that affect only a miniscule percentage of the overall population. Though the market for such drugs is small, it is currently the fastest growing segment of the drug industry because drug manufacturers are getting away with charging upwards of $1 million or more per patient who receives such treatments, and nobody is doing anything to stop them.
If you thought the costs associated with mass-produced patented drugs was high, consider the fact that patients with the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH), for instance, are typically billed a whopping $440,000 per year to be treated with the Alexion Pharmaceuticals drug Soliris (eculizumab). And patients with a rare form of the lung disease cystic fibrosis are currently being charged upwards of $300,000 for treatment with the Vertex Pharmaceuticals drug Kalydeco (ivacaftor).
Where prices really get crazy, though, is with a new drug called Glybera (alipogene tiparvovec), which was recently approved in Europe for the treatment of lipoprotein lipase deficiency (LPLD). According to Reuters, the drug, which is manufactured by the Dutch company UniQure, will cost more than $1 million per patient when it hits the market this summer, and will be among the most expensive drugscurrently available to patients. And the only reason it will cost so much is that UniQure can charge as much as it wants for the drug without penalty, as there are no government-approved alternatives.
A mobile application, also known as a cellular app or perhaps an app, is an application designed for make use of on a smart phone, mobile tablet, or wristwatch. These applications are often used by users to reach applications and content material on the internet. It has being able to connect to an online server...
Fireball slot machine game system matches free of charge on-line, absolutely free video slot machine piece of equipment adventures modest to begin with down payment needed. Poker table pastime and also the accommodations certainly not approved by means of the very first re-opening state; nevertheless, area betting possibilities, by using best community distancing, may turned...
Here you’ll find our rankings of the top US-friendly online casinos of 2020. With mobile real money casinos , you can use your device to access the same benefits and bonuses. Online casino sites tend to support a wide range of payment methods. Our reviewers examine ease-of-navigation and software speed in determining which sites offer...
As any savvy in-bound marketer knows, blogging is a very important tool for bringing the correct visitors to your website. If you were blogging for almost any amount of time, you could have started tinkering with the concept of guest blogging, too. Of course, if you’ve been wavering with this particular idea, we’re here to...
Antivirus application, sometimes recognized ant-malware or perhaps anti-spyware, can be an essential laptop application that is used to identify, block, and eliminate malware from some type of computer. In this article, we will need a look at exactly what is a virus, and why should we consider it? During the past, computers were slow, unimpressive,...